Nanohale AG (ETR:FYB) | Finanzwire

Basculer en Français

9478	Companies
185496	Keywords
117875	Articles
99351	Press releases

Home
Companies
Nanohale AG

BRIEF

published on 06/17/2025 at 08:06, 5 months 18 days ago

Formycon Announces EUR 50 Million Corporate Bond Issuance for Growth

Growth Strategy Corporate Bond Formycon EUR 50 Million Biosimilar Market
PRESS RELEASE

published on 06/17/2025 at 08:01, 5 months 18 days ago

Formycon plans public corporate bond issuance to support next growth phase within attractive Biosimilar markets
Formycon AG plans EUR 50 million corporate bond issuance to support growth in Biosimilar markets. Bond led by IKB Deutsche Industriebank AG & Pareto Securities AS

Formycon AG Growth Corporate Bond IKB Deutsche Industriebank Biosimilar Markets
BRIEF

published on 06/17/2025 at 08:00, 5 months 18 days ago

Formycon to Launch €50 Million Bond for Growth

Growth Strategy Formycon AG Bond Issuance €50 Million Biosimilar Products
PRESS RELEASE

published on 06/17/2025 at 07:55, 5 months 18 days ago

EQS-Adhoc: Formycon plans to issue a public senior unsecured floating rate bond with target volume of EUR 50 million to support further company growth
Formycon AG plans EUR 50 million senior unsecured bond issuance for company growth. Joint Lead Managers: IKB Deutsche Industriebank AG, Pareto Securities AS

Formycon AG Bond Issuance EUR 50 Million Senior Unsecured Joint Lead Managers
BRIEF

published on 06/05/2025 at 06:35, 6 months ago

Lucentis® Biosimilar FYB201/Ranivisio® Gains Approval in Brazil

Formycon AG Retinal Diseases Lucentis® Biosimilar Brazil Approval Biomm Partnership
PRESS RELEASE

published on 06/05/2025 at 06:30, 6 months ago

Lucentis® biosimilar FYB201/Ranivisio® (ranibizumab) approved in Brazil
Brazil approves Formycon AG's Lucentis biosimilar FYB201/Ranivisio, marking the beginning of Latin America rollout. Commercial partnership with Biomm established

Formycon AG Lucentis Biosimilar Brazil Approval Biomm Partnership Market Rollout
BRIEF

published on 05/27/2025 at 14:35, 6 months 9 days ago

Formycon and Fresenius Kabi Launch Otulfi™ in Canada

Canadian Market Patient Support Ustekinumab Biosimilar Chronic Autoimmune Diseases Biologic Therapies
PRESS RELEASE

published on 05/27/2025 at 14:30, 6 months 9 days ago

Formycon and Fresenius Kabi announce the commercial launch of FYB202/Otulfi™, an approved ustekinumab biosimilar in Canada
Formycon and Fresenius Kabi announce commercial launch of FYB202/Otulfi ustekinumab biosimilar in Canada, expanding treatment options for chronic autoimmune diseases

Canada Formycon Fresenius Kabi Ustekinumab Biosimilar FYB202/Otulfi
BRIEF

published on 05/19/2025 at 15:05, 6 months 17 days ago

Formycon and Fresenius Kabi Achieve FDA Interchangeability Approval for FYB202/Otulfi®

FDA Approval Biosimilars Formycon Fresenius Kabi Otulfi®
PRESS RELEASE

published on 05/19/2025 at 15:00, 6 months 17 days ago

Formycon and Fresenius Kabi announce FDA Approval of Interchangeability for FYB202/Otulfi® (ustekinumab-aauz)
Formycon and Fresenius Kabi receive FDA approval for interchangeability of FYB202/Otulfi (ustekinumab-aauz) with Stelara, enhancing patient access to treatment options for inflammatory diseases in the US

FDA Approval Formycon Fresenius Kabi Biologics Interchangeability

Accesswire

Published on 12/05/2025 at 17:00, 15 minutes ago

Three Trillion-Dollar Frontiers, One Technology: How SMX Is Everywhere at Once
Published on 12/05/2025 at 16:00, 1 hour 15 minutes ago

SMX Didn't Change Its Story; The World Finally Connected the Dots
Published on 12/05/2025 at 15:45, 1 hour 30 minutes ago

Critical Elements Announces Closing of C$7.0 Million Bought Deal Life Private Placement
Published on 12/05/2025 at 15:35, 1 hour 40 minutes ago

XCF Global Moves to Double SAF Production with New Rise Reno Expansion
Published on 12/05/2025 at 15:25, 1 hour 50 minutes ago

Usha Resources Provides Corporate Updates

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 17:00, 14 minutes ago

EQS-Adhoc: The NAGA Group AG adjusts guidance for financial year 2025 following continued low volatility and weaker year-end performance
Published on 12/05/2025 at 16:25, 49 minutes ago

4YFN26 Awards: Meet the Top 20 startups building the future
Published on 12/05/2025 at 16:10, 1 hour 5 minutes ago

Reorganization of the Eckert & Ziegler Executive Board
Published on 12/05/2025 at 16:00, 1 hour 15 minutes ago

EQS-Adhoc: TIN INN Holding AG implements financing strategy
Published on 12/05/2025 at 16:00, 1 hour 15 minutes ago

EQS-Adhoc: Amundi Physical Metals plc: Release of the Half-Year Financial Report as of September 30, 2025

Les Echos

Published on 12/05/2025 at 15:10, 2 hours 4 minutes ago

Mersen: Number of shares and voting rights as of November 30, 2025
Published on 12/05/2025 at 08:45, 8 hours 30 minutes ago

Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry
Published on 12/04/2025 at 18:00, 23 hours 15 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 23 hours 30 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 23 hours 31 minutes ago

Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution

View all LES ECHOS COMFI WIRE